NASDAQ: VINCVincerx Pharma Inc Stock
$0.85-0.05 (-5.56%)
Updated Apr 19, 2024
VINC Price
$0.85
Fair Value Price
$0.49
Market Cap
$18.20M
52 Week Low
$0.61
52 Week High
$9.37
P/E
-0.45x
P/B
1.62x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$40.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.62
Operating Cash Flow
-$40M
Beta
0.45
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VINC Overview
Vincerx Pharma Incorparated is a biopharmaceutical company developing therapies to treat cancer. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating advanced cancers. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors, and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincex Pharma was founded in 2019 is headquartered in Palo Alto, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VINC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VINC ($0.85) is overvalued by 74.85% relative to our estimate of its Fair Value price of $0.49 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VINC ($0.85) is not significantly undervalued (74.85%) relative to our estimate of its Fair Value price of $0.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VINC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VINC due diligence checks available for Premium users.
Be the first to know about important VINC news, forecast changes, insider trades & much more!
VINC News
Valuation
VINC fair value
Fair Value of VINC stock based on Discounted Cash Flow (DCF)
Price
$0.85
Fair Value
$0.49
Overvalued by
74.85%
VINC ($0.85) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VINC ($0.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VINC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VINC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.45x
Industry
15.81x
Market
40.51x
VINC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.62x
Industry
5.74x
VINC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VINC's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.0M
Profit Margin
0%
VINC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.2M
Liabilities
$7.0M
Debt to equity
0.62
VINC's short-term assets ($14.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VINC's short-term assets ($14.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VINC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.0M
Investing
$5.8M
Financing
$18.0k
VINC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VINC vs Biotech Stocks
Vincerx Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.